- All patients with metastatic or unresectable melanoma or those at high risk of relapse should be screened for BRAF V600 mutations, preferably in a metastatic lesion, and for adjuvant therapy in the primary tumor to guide therapeutic decision making (56). Here, BRAF is linked to melanoma.